The Biotechnology Industry Organization released a report titled: Emerging Therapeutic Company Investment and Deal Trends. BIO Industry Analysis says more than 90 percent of the biopharma industry is composed of small, emerging companies. According to BIO President Jim Greenwood and E. Cartier Esham, Ph.D., executive VP of BIO’s Emerging Companies Section, it is important for the trade association to better understand early-stage investor and deal-making trends in order to determine where scientific or policy issues may be affecting the ability to maintain a robust pipeline of innovative medicines.

Based on the closing of IMS Health and Quintiles common stock prices on May 2, 2016, the equity market capitalization of the joined companies is more than $17.6 billion and the enterprise value is more than $23 billion.

 Gains full-rights to Padlock’s Protein/Peptidyl Arginine Deiminase (PAD) inhibitor discovery program Expands Bristol-Myers Squibb’s immunoscience pipeline with potentially transformational approach to treating rheumatoid arthritis and other autoimmune diseases   March […]

Newport Beach, CA — March 15, 2016 Glutenase for in-vivo gluten degradation is a leading candidate for celiac disease   ImmunogenX™, a biopharmaceutical company focused on the diagnosis and treatment […]

Addition of Biologic KRYSTEXXA® (pegloticase) Expands and Diversifies Horizon’s Orphan Business; Leverages Rheumatology Expertise and Infrastructure; Transaction Is Expected to Be Immediately Accretive to Adjusted EBITDA in 2016; Conference Call […]

The digital HCP engagement provider Physicians Interactive announced two major strategic moves in the past two months, acquiring the HCP content platform Univadis from Merck in October and then rebranding […]

Strategic Move Enhances Teva’s Presence in Mexico, the Second Largest Market in Latin America and a Major Emerging Market Brings a Portfolio of Differentiated, Patent-Protected, Fixed-Dose Medicine Combinations, Strong Brand […]

Pharmaceutical company Mallinckrodt PLC said its profit soared in the latest quarter as the company’s specialty brand sales continue to benefit from recent acquisitions. But overall sales missed analysts’ lofty […]

A year ago Shire shares were punished when the U.S. Treasury’s freeze on so-called inversion transactions nixed the company’s sale to AbbVie, a Chicago-based pharma giant looking to save money on […]

By Anna Wilde Mathews The Wall Street Journal Biography @annawmathews [email protected] July 29, 2015 6:55 p.m. ET   The leaders of the top five health insurers periodically get together to […]